207 related articles for article (PubMed ID: 25125498)
1. Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Bowles EA; Moody GN; Yeragunta Y; Stephenson AH; Ellsworth ML; Sprague RS
Exp Biol Med (Maywood); 2015 Jan; 240(1):121-7. PubMed ID: 25125498
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Knebel SM; Elrick MM; Bowles EA; Zdanovec AK; Stephenson AH; Ellsworth ML; Sprague RS
Exp Biol Med (Maywood); 2013 Sep; 238(9):1069-74. PubMed ID: 23986226
[TBL] [Abstract][Full Text] [Related]
3. Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes.
Bowles EA; Feys D; Ercal N; Sprague RS
Biochem Biophys Rep; 2017 Dec; 12():114-119. PubMed ID: 28955799
[TBL] [Abstract][Full Text] [Related]
4. Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes.
Sprague RS; Bowles EA; Hanson MS; DuFaux EA; Sridharan M; Adderley S; Ellsworth ML; Stephenson AH
Microcirculation; 2008 Jul; 15(5):461-71. PubMed ID: 18574748
[TBL] [Abstract][Full Text] [Related]
5. Prostacyclin receptor-mediated ATP release from erythrocytes requires the voltage-dependent anion channel.
Sridharan M; Bowles EA; Richards JP; Krantic M; Davis KL; Dietrich KA; Stephenson AH; Ellsworth ML; Sprague RS
Am J Physiol Heart Circ Physiol; 2012 Feb; 302(3):H553-9. PubMed ID: 22159995
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5.
Adderley SP; Thuet KM; Sridharan M; Bowles EA; Stephenson AH; Ellsworth ML; Sprague RS
Med Sci Monit; 2011 May; 17(5):CR241-7. PubMed ID: 21525805
[TBL] [Abstract][Full Text] [Related]
7. Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Hori Y; Kondo C; Matsui M; Yamagishi M; Okano S; Chikazawa S; Kanai K; Hoshi F; Itoh N
Vet J; 2014 Nov; 202(2):334-9. PubMed ID: 25178687
[TBL] [Abstract][Full Text] [Related]
8. Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.
Aronsen L; Orvoll E; Lysaa R; Ravna AW; Sager G
Eur J Pharmacol; 2014 Dec; 745():249-53. PubMed ID: 25445042
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
10. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.
Falk JA; Philip KJ; Schwarz ER
Vasc Health Risk Manag; 2010 May; 6():273-80. PubMed ID: 20479949
[TBL] [Abstract][Full Text] [Related]
11. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
13. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang I
Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827
[TBL] [Abstract][Full Text] [Related]
14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Sawamura F; Kato M; Fujita K; Nakazawa T; Beardsworth A
J Pharmacol Sci; 2009 Nov; 111(3):235-43. PubMed ID: 19881228
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
17. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.
Falcetti E; Hall SM; Phillips PG; Patel J; Morrell NW; Haworth SG; Clapp LH
Am J Respir Crit Care Med; 2010 Nov; 182(9):1161-70. PubMed ID: 20622039
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with type 2 diabetes.
Richards JP; Bowles EA; Gordon WR; Ellsworth ML; Stephenson AH; Sprague RS
Am J Physiol Regul Integr Comp Physiol; 2015 Mar; 308(5):R411-8. PubMed ID: 25552662
[TBL] [Abstract][Full Text] [Related]
19. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
Dandel M; Hetzer R
Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
